335 related articles for article (PubMed ID: 11520213)
1. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
Habeeb AG; Praveen Rao PN; Knaus EE
J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere.
Uddin MJ; Rao PN; Knaus EE
Bioorg Med Chem; 2003 Nov; 11(23):5273-80. PubMed ID: 14604691
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Navidpour L; Amini M; Shafaroodi H; Abdi K; Ghahremani MH; Dehpour AR; Shafiee A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4483-7. PubMed ID: 16806914
[TBL] [Abstract][Full Text] [Related]
5. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Everts B; Währborg P; Hedner T
Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
[TBL] [Abstract][Full Text] [Related]
6. Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors.
Rahim MA; Rao PN; Knaus EE
Bioorg Med Chem Lett; 2002 Oct; 12(19):2753-6. PubMed ID: 12217369
[TBL] [Abstract][Full Text] [Related]
7. Tracing the origins of COX-2 inhibitors' structures.
Lednicer D
Curr Med Chem; 2002 Aug; 9(15):1457-61. PubMed ID: 12173976
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
Palomer A; Cabré F; Pascual J; Campos J; Trujillo MA; Entrena A; Gallo MA; García L; Mauleón D; Espinosa A
J Med Chem; 2002 Mar; 45(7):1402-11. PubMed ID: 11906281
[TBL] [Abstract][Full Text] [Related]
9. 4-substituted 1,5-diarylpyrazole, analogues of celecoxib: synthesis and preliminary evaluation of biological properties.
Menozzi G; Merello L; Fossa P; Mosti L; Piana A; Mattioli F
Farmaco; 2003 Sep; 58(9):795-808. PubMed ID: 13679172
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity.
Habeeb AG; Praveen Rao PN; Knaus EE
J Med Chem; 2001 Aug; 44(18):2921-7. PubMed ID: 11520200
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.
Price ML; Jorgensen WL
Bioorg Med Chem Lett; 2001 Jun; 11(12):1541-4. PubMed ID: 11412976
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.
Yamakawa N; Suzuki K; Yamashita Y; Katsu T; Hanaya K; Shoji M; Sugai T; Mizushima T
Bioorg Med Chem; 2014 Apr; 22(8):2529-34. PubMed ID: 24650702
[TBL] [Abstract][Full Text] [Related]
13. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Pinheiro RM; Calixto JB
Inflamm Res; 2002 Dec; 51(12):603-10. PubMed ID: 12558194
[TBL] [Abstract][Full Text] [Related]
14. Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor.
Zarghi A; Praveen Rao PN; Knaus EE
Bioorg Med Chem Lett; 2004 Apr; 14(8):1957-60. PubMed ID: 15050636
[TBL] [Abstract][Full Text] [Related]
15. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory 2-benzyl-4-sulfonyl-4H-isoquinoline-1,3-diones: novel inhibitors of COX-2.
Lazer ES; Sorcek R; Cywin CL; Thome D; Possanza GJ; Graham AG; Churchill L
Bioorg Med Chem Lett; 1998 May; 8(10):1181-6. PubMed ID: 9871731
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Aug; 13(15):4694-703. PubMed ID: 15914011
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
Mazario J; Gaitan G; Herrero JF
Neuropharmacology; 2001 Jun; 40(7):937-46. PubMed ID: 11378164
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic advances with coxibs: few certainties and a lot of doubts].
Jouzeau JY; Daouphars M; Netter P
Therapie; 2004; 59(2):207-11. PubMed ID: 15359614
[No Abstract] [Full Text] [Related]
[Next] [New Search]
